GlassScriptPhysician profile
Harry G Blackstone
NPI 1720016496
$9,592.24
in general payments reported to CMS, 2019-2025
38 companies · $1,083 in 2025
The $1,083 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,315 · 2020: $1,493 · 2021: $2,022 · 2022: $1,662 · 2023: $1,093 · 2024: $925 · 2025: $1,083.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,100.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,855.00 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $837.02 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $833.76 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $828.80 | 2019-2025 | Otezla, Repatha, Repatha |
| Pfizer INC. | $696.24 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $530.81 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Janssen Pharmaceuticals, INC | $452.97 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $390.20 | 2019-2025 | |
| Glaxosmithkline, LLC. | $339.28 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Sanofi-Aventis U.S. LLC | $333.82 | 2019-2023 | |
| Amarin Pharma, INC. | $294.80 | 2020-2022 | |
| Abbvie INC. | $291.60 | 2021-2024 | Qulipta, Ubrelvy, Viberzi |
| Sumitomo Pharma America, INC. | $264.84 | 2023-2025 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $210.86 | 2019-2024 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $188.45 | 2022-2025 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $151.12 | 2021-2024 | Dexcom G6 Transmitter |
| Abbott Laboratories | $144.53 | 2020-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $99.39 | 2019-2022 | |
| Astellas Pharma US INC | $96.20 | 2021-2024 | Veozah, Myrbetriq |
| Exact Sciences Corporation | $93.79 | 2024 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $86.69 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $78.04 | 2020-2023 | Livalo, Seglentis |
| Nevro Corp. | $73.64 | 2022-2023 | Senza |
| Sunovion Pharmaceuticals INC. | $65.06 | 2022 | |
| Boston Scientific Corporation | $61.52 | 2024-2025 | General - Pain Management, Watchman Flx |
| Eisai INC. | $58.13 | 2021 | |
| Corcept Therapeutics | $34.04 | 2025 | Korlym |
| E.R. Squibb & Sons, L.L.C. | $28.21 | 2021-2022 | |
| Ibsa Pharma INC. | $27.09 | 2020 | |
| Phathom Pharmaceuticals, INC. | $24.65 | 2025 | Voquezna |
| Amneal Pharmaceuticals LLC | $19.22 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.11 | 2022 | |
| Lifescan, INC. | $16.75 | 2022 | |
| Xeris Pharmaceuticals, INC. | $16.24 | 2021 | |
| Medtronic, INC. | $14.45 | 2022 | |
| Paratek Pharmaceuticals, INC. | $13.93 | 2024 | Nuzyra |
| Ethicon US, LLC | $12.97 | 2019 | |
| Mannkind Corporation | $11.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harry Blackstone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.